Disease Information
General Information of the Disease (ID: DIS00069)
Name |
Oral squamous cell carcinoma
|
---|---|
ICD |
ICD-11: 2B6E
|
Resistance Map |
Type(s) of Resistant Mechanism of This Disease
EADR: Epigenetic Alteration of DNA, RNA or Protein
IDUE: Irregularity in Drug Uptake and Drug Efflux
RTDM: Regulation by the Disease Microenvironment
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
7 drug(s) in total
Cetuximab
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa_circ_0005379 | [1] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cetuximab | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
EGFR signaling pathway | Inhibition | hsa01521 | ||
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
SCC25 cells | Oral | Homo sapiens (Human) | CVCL_1682 | |
In Vivo Model | Balb/c athymic nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | Upregualtion of hsa_circ_0005379 enhances the sensitivity of OSCC to anticancer drug cetuximab. |
Cisplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-654-5p | [2] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | MAPK/RAS signaling pathway | Regulation | hsa04010 | |
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPk signaling. | |||
Key Molecule: CDKN2B antisense RNA 1 (CDKN2B-AS1) | [3] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Caspase-3 signaling pathway | Activation | hsa04210 | |
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
HSC3 cells | Tongue | Homo sapiens (Human) | CVCL_1288 | |
HaCaT cells | Tongue | Homo sapiens (Human) | CVCL_0038 | |
OSCC3 cells | Tongue | Homo sapiens (Human) | CVCL_L894 | |
SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of LncRNA ANRIL in tumour cells. ANRIL knockdown overcomes Mk-induced cisplatin resistance via activation of caspase-3-dependent apoptosis. Overexpression of LncRNA ANRIL promots the up-regulation of ABC family proteins MRP1 and ABCC2, which ultimately results in tumour cell resistance to cisplatin. | |||
Key Molecule: hsa-miR-184 | [4] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 | |
NHOk cells | Tongue | Homo sapiens (Human) | N.A. | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
TSCCA cells | Tongue | Homo sapiens (Human) | CVCL_VL15 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-qPCR; Dual luciferase reporter assay | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Caspase-3 activity analysis | |||
Mechanism Description | LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. | |||
Key Molecule: Urothelial cancer associated 1 (UCA1) | [4] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 | |
NHOk cells | Tongue | Homo sapiens (Human) | N.A. | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
TSCCA cells | Tongue | Homo sapiens (Human) | CVCL_VL15 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Caspase-3 activity analysis | |||
Mechanism Description | LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. | |||
Key Molecule: hsa-mir-218 | [5] | |||
Resistant Disease | Oral cancer [ICD-11: 2B6E.1] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | PPP2R5A/Wnt signaling pathway | Regulation | hsa04310 | |
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 | |
SCC25 cells | Oral | Homo sapiens (Human) | CVCL_1682 | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
MDA-1386Ln cells | Tongue | Homo sapiens (Human) | CVCL_H541 | |
SCC15 cells | Tongue | Homo sapiens (Human) | CVCL_1681 | |
UM1 cells | Tongue | Homo sapiens (Human) | CVCL_VH00 | |
UM2 cells | Tongue | Homo sapiens (Human) | CVCL_VH01 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | microRNA-218 promotes cisplatin resistance in oral cancer via the PPP2R5A/Wnt signaling pathway. Suppression of miR218 or PPP2R5A significantly promoted or reduced cisplatin-induced apoptosis, respectively. PPP2R5A overexpression or beta-catenin knockdown inhibited miR218-mediated Wnt activation and partially restored cell sensitivity. | |||
Key Molecule: Long noncoding RNA lnc-IL7R (Lnc-IL7R) | [6] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
HSC3 cells | Tongue | Homo sapiens (Human) | CVCL_1288 | |
HaCaT cells | Tongue | Homo sapiens (Human) | CVCL_0038 | |
OSCC3 cells | Tongue | Homo sapiens (Human) | CVCL_L894 | |
SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 | |
HIOEC-B cells | Tongue | Homo sapiens (Human) | CVCL_6E44 | |
SCC-14a cells | Tongue | Homo sapiens (Human) | CVCL_7719 | |
SCC-14b cells | Tongue | Homo sapiens (Human) | CVCL_7720 | |
SCC1 cells | Tongue | Homo sapiens (Human) | CVCL_A5SA | |
Experiment for Molecule Alteration |
Q-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | TLR3 negatively manipulated the inflammation-related long noncoding RNA lnc-IL7R, knockdown of lnc-IL7R improved the chemotherapy sensitivity. | |||
Key Molecule: Toll-like receptor 3 (TLR3) | [6] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
HSC3 cells | Tongue | Homo sapiens (Human) | CVCL_1288 | |
HaCaT cells | Tongue | Homo sapiens (Human) | CVCL_0038 | |
OSCC3 cells | Tongue | Homo sapiens (Human) | CVCL_L894 | |
SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 | |
HIOEC-B cells | Tongue | Homo sapiens (Human) | CVCL_6E44 | |
SCC-14a cells | Tongue | Homo sapiens (Human) | CVCL_7719 | |
SCC-14b cells | Tongue | Homo sapiens (Human) | CVCL_7720 | |
SCC1 cells | Tongue | Homo sapiens (Human) | CVCL_A5SA | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | TLR3 negatively manipulated the inflammation-related long noncoding RNA lnc-IL7R, knockdown of lnc-IL7R improved the chemotherapy sensitivity. | |||
Key Molecule: hsa-mir-29a | [7] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
In Vitro Model | SCC25 cells | Oral | Homo sapiens (Human) | CVCL_1682 |
SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-29a expression was decreased in clinical OSCC cancer specimens. miR-29a negatively regulated MMP2 transcription and translation through directly binding to 3'-UTR. miR-29a overexpression could inhibit OSCC cancer cell invasion and anti-apoptotic ability, and vice versa. | |||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ATP-binding cassette sub-family C2 (ABCC2) | [3] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Caspase-3 signaling pathway | Activation | hsa04210 | |
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
HSC3 cells | Tongue | Homo sapiens (Human) | CVCL_1288 | |
HaCaT cells | Tongue | Homo sapiens (Human) | CVCL_0038 | |
OSCC3 cells | Tongue | Homo sapiens (Human) | CVCL_L894 | |
SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of LncRNA ANRIL in tumour cells. ANRIL knockdown overcomes Mk-induced cisplatin resistance via activation of caspase-3-dependent apoptosis. Overexpression of LncRNA ANRIL promots the up-regulation of ABC family proteins MRP1 and ABCC2, which ultimately results in tumour cell resistance to cisplatin. | |||
Key Molecule: Multidrug resistance-associated protein 1 (MRP1) | [3] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Caspase-3 signaling pathway | Activation | hsa04210 | |
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
HSC3 cells | Tongue | Homo sapiens (Human) | CVCL_1288 | |
HaCaT cells | Tongue | Homo sapiens (Human) | CVCL_0038 | |
OSCC3 cells | Tongue | Homo sapiens (Human) | CVCL_L894 | |
SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of LncRNA ANRIL in tumour cells. ANRIL knockdown overcomes Mk-induced cisplatin resistance via activation of caspase-3-dependent apoptosis. Overexpression of LncRNA ANRIL promots the up-regulation of ABC family proteins MRP1 and ABCC2, which ultimately results in tumour cell resistance to cisplatin. | |||
Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [8] | |||
Resistant Disease | Oral cancer [ICD-11: 2B6E.1] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | UM-SCC-1 cells | Ovary | Homo sapiens (Human) | CVCL_7707 |
WSU-HN30 cells | Pleural effusion | Homo sapiens (Human) | CVCL_5525 | |
WSU-HN6 cells | Urinary bladder | Homo sapiens (Human) | CVCL_5516 | |
Experiment for Molecule Alteration |
qRT-PCR; Western blotting assay | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | E-cigarette aerosol exposure alters the expression of drug influx and efflux transporters.Among the other drug efflux ATPase genes previously reported to contribute to cisplatin resistance ABCG2, ABCC2, ABCA1, and ABCC1 were significantly up-regulated in at least one cell line. | |||
Regulation by the Disease Microenvironment (RTDM) | ||||
Key Molecule: Collagenase 72 kDa type IV collagenase (MMP2) | [7] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
In Vitro Model | SCC25 cells | Oral | Homo sapiens (Human) | CVCL_1682 |
SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-29a expression was decreased in clinical OSCC cancer specimens. miR-29a negatively regulated MMP2 transcription and translation through directly binding to 3'-UTR. miR-29a overexpression could inhibit OSCC cancer cell invasion and anti-apoptotic ability, and vice versa. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: GRB2-related adapter protein (GRAP) | [2] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | MAPK/RAS signaling pathway | Regulation | hsa04010 | |
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPk signaling. | |||
Key Molecule: Steroidogenic factor 1 (STF1) | [4] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell adhesion | Activation | hsa04514 | |
Cell invasion | Activation | hsa05200 | ||
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 | |
NHOk cells | Tongue | Homo sapiens (Human) | N.A. | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
TSCCA cells | Tongue | Homo sapiens (Human) | CVCL_VL15 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Caspase-3 activity analysis | |||
Mechanism Description | UCA1 accelerated proliferation, increased CDDP chemoresistance and restrained apoptosis partly through modulating SF1 via sponging miR-184 in OSCC cells. UCA1 promoted the expression of SF1 by sponging miR-184 in CDDP-resistant OSCC cells. | |||
Key Molecule: PP2A B subunit isoform R5-alpha (PPP2R5A) | [5] | |||
Resistant Disease | Oral cancer [ICD-11: 2B6E.1] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | PPP2R5A/Wnt signaling pathway | Regulation | hsa04310 | |
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 | |
SCC25 cells | Oral | Homo sapiens (Human) | CVCL_1682 | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
MDA-1386Ln cells | Tongue | Homo sapiens (Human) | CVCL_H541 | |
SCC15 cells | Tongue | Homo sapiens (Human) | CVCL_1681 | |
UM1 cells | Tongue | Homo sapiens (Human) | CVCL_VH00 | |
UM2 cells | Tongue | Homo sapiens (Human) | CVCL_VH01 | |
Experiment for Molecule Alteration |
qRT-PCR; Western blot analysis; Dual luciferase reporter assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | microRNA-218 promotes cisplatin resistance in oral cancer via the PPP2R5A/Wnt signaling pathway. Suppression of miR218 or PPP2R5A significantly promoted or reduced cisplatin-induced apoptosis, respectively. PPP2R5A overexpression or beta-catenin knockdown inhibited miR218-mediated Wnt activation and partially restored cell sensitivity. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-27b | [9] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
FZD7/beta-catenin signaling pathway | Activation | hsa05224 | ||
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
Colony formation assay; Flow cytometry assay | |||
Mechanism Description | miR-27b can increase the sensitivity of OSCC cells to cisplatin drugs, significantly inhibit OSCC cell proliferation, promote cell apoptosis, and inhibit cell invasion and migration, which may be related to the inhibition of FDZ7/beta-catenin signaling pathway by miR-27b. | |||
Key Molecule: HOX transcript antisense RNA (HOTAIR) | [10] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell autophagy | Activation | hsa04140 | |
In Vitro Model | CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 |
KB cells | Gastric | Homo sapiens (Human) | CVCL_0372 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | After HOTAIR silence, autophagy was inhibited with the downregulated expression of MAP1LC3B (microtubule-associated protein 1 light chain 3B), beclin1, and autophagy-related gene (ATG) 3 and ATG7. The expressions of mTOR increased, which promoted the sensitivity to cisplatin. | |||
Key Molecule: hsa-let-7c | [11] | |||
Sensitive Disease | Oral cancer [ICD-11: 2B6E.1] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Inhibition | hsa05200 | |
In Vitro Model | GNM cells | Oral | Homo sapiens (Human) | CVCL_WL58 |
SAS cells | Oral | Homo sapiens (Human) | CVCL_1675 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The inhibitory effect of let-7c on various stemness phenotypes was reverted by IL-8, indicating that lower expression of let-7c may confer higher cancer stemness through a failure to downregulate IL-8. | |||
Key Molecule: hsa-mir-222 | [12] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | UM1 cells | Tongue | Homo sapiens (Human) | CVCL_VH00 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Antisense (As)-miR-222 inhibits the expression of miR-222. In contrast, PUMA was dramaticallyup-regulated. IC50 values were significantly decreased in cells treated with As-miR-222 combined with CDDP, to a greater extent than in cells treated with CDDP alone. Furthermore, As-miR-222 (+) apoptosis and inhibited the invasiveness of UM1 cells. Analysis of the above data suggested that, in UM1 cells, there might be a regulatory loop between miR-222 and PUMA, and that miR-222 inhibition increased the chemosensitivity to CDDP. | |||
Regulation by the Disease Microenvironment (RTDM) | ||||
Key Molecule: Cadherin-1 (CDH1) | [13] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Activation | hsa05200 | |
Cell viability | Inhibition | hsa05200 | ||
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
SCC25 cells | Oral | Homo sapiens (Human) | CVCL_1682 | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
SCC15 cells | Tongue | Homo sapiens (Human) | CVCL_1681 | |
In Vivo Model | BALB/c nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | HULC-depleted cells showed decreased expression of vimentin and N-cadherin and increased expression of E-cadherin, which shows that HULC participates in the EMT process and affects the expression levels of proteins that are crucial for cell proliferation and invasion. | |||
Key Molecule: Hepatocellular carcinoma up-regulated long non-coding RNA (HULC) | [13] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
Cell viability | Inhibition | hsa05200 | ||
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
SCC25 cells | Oral | Homo sapiens (Human) | CVCL_1682 | |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
SCC15 cells | Tongue | Homo sapiens (Human) | CVCL_1681 | |
In Vivo Model | BALB/c nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | HULC-depleted cells showed decreased expression of vimentin and N-cadherin and increased expression of E-cadherin, which shows that HULC participates in the EMT process and affects the expression levels of proteins that are crucial for cell proliferation and invasion. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Serine/threonine-protein kinase mTOR (mTOR) | [10] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell autophagy | Inhibition | hsa04140 | ||
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 |
KB cells | Gastric | Homo sapiens (Human) | CVCL_0372 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | After HOTAIR silence, autophagy was inhibited with the downregulated expression of MAP1LC3B (microtubule-associated protein 1 light chain 3B), beclin1, and autophagy-related gene (ATG) 3 and ATG7. The expressions of mTOR increased, which promoted the sensitivity to cisplatin. | |||
Key Molecule: Ubiquitin-like-conjugating enzyme ATG3 (ATG3) | [10] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell autophagy | Inhibition | hsa04140 | ||
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 |
KB cells | Gastric | Homo sapiens (Human) | CVCL_0372 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | After HOTAIR silence, autophagy was inhibited with the downregulated expression of MAP1LC3B (microtubule-associated protein 1 light chain 3B), beclin1, and autophagy-related gene (ATG) 3 and ATG7. The expressions of mTOR increased, which promoted the sensitivity to cisplatin. | |||
Key Molecule: Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) | [10] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell autophagy | Inhibition | hsa04140 | ||
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 |
KB cells | Gastric | Homo sapiens (Human) | CVCL_0372 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | After HOTAIR silence, autophagy was inhibited with the downregulated expression of MAP1LC3B (microtubule-associated protein 1 light chain 3B), beclin1, and autophagy-related gene (ATG) 3 and ATG7. The expressions of mTOR increased, which promoted the sensitivity to cisplatin. | |||
Key Molecule: Beclin-1 (BECN1) | [10] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell autophagy | Inhibition | hsa04140 | ||
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 |
KB cells | Gastric | Homo sapiens (Human) | CVCL_0372 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | After HOTAIR silence, autophagy was inhibited with the downregulated expression of MAP1LC3B (microtubule-associated protein 1 light chain 3B), beclin1, and autophagy-related gene (ATG) 3 and ATG7. The expressions of mTOR increased, which promoted the sensitivity to cisplatin. | |||
Key Molecule: Autophagy-related protein LC3 B (MAP1LC3B) | [10] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell autophagy | Inhibition | hsa04140 | ||
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 |
KB cells | Gastric | Homo sapiens (Human) | CVCL_0372 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | After HOTAIR silence, autophagy was inhibited with the downregulated expression of MAP1LC3B (microtubule-associated protein 1 light chain 3B), beclin1, and autophagy-related gene (ATG) 3 and ATG7. The expressions of mTOR increased, which promoted the sensitivity to cisplatin. | |||
Key Molecule: Interleukin-8 (IL8) | [11] | |||
Sensitive Disease | Oral cancer [ICD-11: 2B6E.1] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Inhibition | hsa05200 | |
In Vitro Model | GNM cells | Oral | Homo sapiens (Human) | CVCL_WL58 |
SAS cells | Oral | Homo sapiens (Human) | CVCL_1675 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The inhibitory effect of let-7c on various stemness phenotypes was reverted by IL-8, indicating that lower expression of let-7c may confer higher cancer stemness through a failure to downregulate IL-8. | |||
Key Molecule: Bcl-2-binding component 3 (BBC3) | [12] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | UM1 cells | Tongue | Homo sapiens (Human) | CVCL_VH00 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Antisense (As)-miR-222 inhibits the expression of miR-222. In contrast, PUMA was dramaticallyup-regulated. IC50 values were significantly decreased in cells treated with As-miR-222 combined with CDDP, to a greater extent than in cells treated with CDDP alone. Furthermore, As-miR-222 (+) apoptosis and inhibited the invasiveness of UM1 cells. Analysis of the above data suggested that, in UM1 cells, there might be a regulatory loop between miR-222 and PUMA, and that miR-222 inhibition increased the chemosensitivity to CDDP. |
Docetaxel
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [14] | |||
Resistant Disease | Squamous cell carcinoma [ICD-11: 2B6E.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Docetaxel | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | KB-3-1 cells | Lung | Homo sapiens (Human) | CVCL_2088 |
KB-8-5 cells | Mouth | Homo sapiens (Human) | CVCL_5994 | |
KB-V1 cells | Mouth | Homo sapiens (Human) | CVCL_2089 | |
In Vivo Model | Athymic nu/nu female mice xenograft model | Mus musculus | ||
Experiment for Drug Resistance |
MTS assay | |||
Mechanism Description | In a cell line expressing a high level of P-glycoprotein, the IC50 of TTI-237 increased 25-fold whereas those of paclitaxel and vincristine increased 806-fold and 925-fold. |
Doxorubicin
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-221 | [15] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
Annexin V-fluorescein isothiocyanate (FITC)/Hoechst double staining; MTT assay | |||
Mechanism Description | OSCC cells are resistant to doxorubicin through upregulation of miR221, which in turn downregulates TIMP3. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Metalloproteinase inhibitor 3 (TIMP3) | [15] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | SCC4 cells | Tongue | Homo sapiens (Human) | CVCL_1684 |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
Experiment for Molecule Alteration |
Western blot analysis; Luciferase reporter assay | |||
Experiment for Drug Resistance |
Annexin V-fluorescein isothiocyanate (FITC)/Hoechst double staining; MTT assay | |||
Mechanism Description | OSCC cells are resistant to doxorubicin through upregulation of miR221, which in turn downregulates TIMP3. |
Fluorouracil
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-654-5p | [2] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Fluorouracil | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | MAPK/RAS signaling pathway | Regulation | hsa04010 | |
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPk signaling. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: GRB2-related adapter protein (GRAP) | [2] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Fluorouracil | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | MAPK/RAS signaling pathway | Regulation | hsa04010 | |
In Vitro Model | Tca8113 cells | Tongue | Homo sapiens (Human) | CVCL_6851 |
CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPk signaling. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-365a-3p | [16] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Fluorouracil | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Beta5-integrin/c-Met signaling pathway | Inhibition | hsa01521 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | C9-IV3 cells | Oral | Homo sapiens (Human) | N.A. |
CGHNC9 cells | Oral | Homo sapiens (Human) | N.A. | |
OC-3 cells | Oral | Homo sapiens (Human) | CVCL_WL09 | |
In Vivo Model | CB17-SCID mice xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-365-3p targets EHF to inhibit OSCC migration, invasion, and metastasis through kRT16. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: ETS homologous factor (EHF) | [16] | |||
Sensitive Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Fluorouracil | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Beta5-integrin/c-Met signaling pathway | Inhibition | hsa01521 | |
Cell apoptosis | Activation | hsa04210 | ||
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell viability | Inhibition | hsa05200 | ||
In Vitro Model | C9-IV3 cells | Oral | Homo sapiens (Human) | N.A. |
CGHNC9 cells | Oral | Homo sapiens (Human) | N.A. | |
OC-3 cells | Oral | Homo sapiens (Human) | CVCL_WL09 | |
In Vivo Model | CB17-SCID mice xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-365-3p targets EHF to inhibit OSCC migration, invasion, and metastasis through kRT16. |
Paclitaxel
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ATP-binding cassette sub-family B5 (ABCB5) | [17] | |||
Sensitive Disease | Squamous cell carcinoma [ICD-11: 2B6E.3] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Paclitaxel | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | KB-3-1 cells | Lung | Homo sapiens (Human) | CVCL_2088 |
KB-8-5 cells | Mouth | Homo sapiens (Human) | CVCL_5994 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The continuous administration of low dose 5FU with Taxol significantly inhibited the tumor growth. The treatment overcomes drug resistance in tumors by down-regulating multi-drug resistance transporter protein. |
Vinblastine
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [14] | |||
Resistant Disease | Squamous cell carcinoma [ICD-11: 2B6E.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Vinblastine | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | KB-3-1 cells | Lung | Homo sapiens (Human) | CVCL_2088 |
KB-8-5 cells | Mouth | Homo sapiens (Human) | CVCL_5994 | |
KB-V1 cells | Mouth | Homo sapiens (Human) | CVCL_2089 | |
In Vivo Model | Athymic nu/nu female mice xenograft model | Mus musculus | ||
Experiment for Drug Resistance |
MTS assay | |||
Mechanism Description | In a cell line expressing a high level of P-glycoprotein, the IC50 of TTI-237 increased 25-fold whereas those of paclitaxel and vincristine increased 806-fold and 925-fold. |
Discontinued Drug(s)
1 drug(s) in total
Cevipabulin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [14] | |||
Resistant Disease | Squamous cell carcinoma [ICD-11: 2B6E.3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cevipabulin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | KB-3-1 cells | Lung | Homo sapiens (Human) | CVCL_2088 |
KB-8-5 cells | Mouth | Homo sapiens (Human) | CVCL_5994 | |
KB-V1 cells | Mouth | Homo sapiens (Human) | CVCL_2089 | |
In Vivo Model | Athymic nu/nu female mice xenograft model | Mus musculus | ||
Experiment for Drug Resistance |
MTS assay | |||
Mechanism Description | The compound was a weak substrate of multidrug resistance 1 (multidrug resistance transporter or P-glycoprotein). In a cell line expressing a high level of P-glycoprotein, the IC50 of TTI-237 increased 25-fold whereas those of paclitaxel and vincristine increased 806-fold and 925-fold, respectively. |
Investigative Drug(s)
1 drug(s) in total
Succinate
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Maternally expressed 3 (MEG3) | [18] | |||
Resistant Disease | Oral squamous cell carcinoma [ICD-11: 2B6E.0] | |||
Molecule Alteration | . | Expression |
||
Resistant Drug | Succinate | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | CAL-27 cells | Tongue | Homo sapiens (Human) | CVCL_1107 |
OLP type I keratinocytes | N.A. | . | N.A. | |
Experiment for Drug Resistance |
Cell Titer-Glo assay; IC50 assay | |||
Mechanism Description | The critical roles of succinate and MEG3 in the metabolic changes during malignant transformation from OLP to OSCC. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.